ARCTArcturus Therapeutics Holdings Inc

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Arcturus Therapeutics Holdings Inc. (Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help...

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in New York: 2026 Jefferies...

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +16.91% and -73.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today...

Arcturus Therapeutics (NASDAQ:ARCT) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...

Illumina (ILMN) delivered earnings and revenue surprises of +9.70% and +1.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Arcturus Therapeutics (NASDAQ:ARCT) Stock Passes Below 200-Day Moving Average - What's Next...

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today...